Triple–negative breast cancer (TNBC) accounts for approximately 10–24% of all breast cancer cases, and it is distinguished by a lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression [2]. This evidence concerns the gene ESR1 and breast cancer.